See more : Nihon Trim Co., Ltd. (6788.T) Income Statement Analysis – Financial Results
Complete financial analysis of Kymera Therapeutics, Inc. (KYMR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kymera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- HMG/Courtland Properties, Inc. (HMG) Income Statement Analysis – Financial Results
- Propanc Biopharma, Inc. (PPCB) Income Statement Analysis – Financial Results
- Golden Valley Development, Inc (GVDI) Income Statement Analysis – Financial Results
- Financial Strategies Acquisition Corp. (FXCOW) Income Statement Analysis – Financial Results
- Tsann Kuen (China) Enterprise Co., Ltd. (200512.SZ) Income Statement Analysis – Financial Results
Kymera Therapeutics, Inc. (KYMR)
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 78.59M | 46.83M | 72.83M | 34.03M | 2.93M | 0.00 |
| Cost of Revenue | 189.08M | 2.98M | 2.40M | 62.11M | 825.00K | 205.00K |
| Gross Profit | -110.49M | 43.85M | 70.44M | -28.07M | 2.11M | -205.00K |
| Gross Profit Ratio | -140.59% | 93.64% | 96.71% | -82.48% | 71.88% | 0.00% |
| Research & Development | 189.08M | 164.25M | 137.02M | 62.11M | 37.16M | 17.68M |
| General & Administrative | 55.04M | 43.83M | 36.35M | 18.23M | 7.98M | 3.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 55.04M | 43.83M | 36.35M | 18.23M | 7.98M | 3.77M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M | 21.45M |
| Cost & Expenses | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M | 21.45M |
| Interest Income | 18.76M | 6.62M | 488.00K | 826.00K | 1.01M | 0.00 |
| Interest Expense | 196.00K | 176.00K | 175.00K | 115.00K | 46.00K | 16.00K |
| Depreciation & Amortization | 3.57M | 2.98M | 2.40M | 1.76M | 825.00K | 205.00K |
| EBITDA | -143.20M | -151.66M | -97.65M | -43.72M | -40.38M | -21.25M |
| EBITDA Ratio | -182.21% | -330.23% | -137.36% | -133.63% | -1,376.11% | 0.00% |
| Operating Income | -165.53M | -161.26M | -100.53M | -46.30M | -42.21M | -21.45M |
| Operating Income Ratio | -210.62% | -344.37% | -138.03% | -136.05% | -1,438.48% | 0.00% |
| Total Other Income/Expenses | 18.57M | 6.45M | 313.00K | 711.00K | 959.00K | -16.00K |
| Income Before Tax | -146.96M | -154.81M | -100.22M | -45.59M | -41.25M | -21.47M |
| Income Before Tax Ratio | -186.99% | -330.60% | -137.60% | -133.96% | -1,405.79% | 0.00% |
| Income Tax Expense | 0.00 | -2.98M | -2.22M | -1.65M | 46.00K | 43.86K |
| Net Income | -146.96M | -151.83M | -98.00M | -43.95M | -41.29M | -21.47M |
| Net Income Ratio | -186.99% | -324.25% | -134.55% | -129.12% | -1,407.36% | 0.00% |
| EPS | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| EPS Diluted | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| Weighted Avg Shares Out | 58.37M | 53.93M | 47.99M | 17.35M | 44.53M | 44.53M |
| Weighted Avg Shares Out (Dil) | 58.37M | 53.93M | 47.99M | 17.35M | 44.53M | 44.53M |
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kymera (KYMR) to Raise $225 Million Through Offering of Shares
Kymera Therapeutics Announces Pricing of $225 Million Public Offering
Kymera Therapeutics Announces Proposed Public Offering
Source: https://incomestatements.info
Category: Stock Reports